passive immunotherapy


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to passive immunotherapy: active immunotherapy

passive immunotherapy

The prevention of disease by administering antibodies in the form of a gamma globulin infusion or injection. Preparations enriched with specific antibodies can be used to prevent hepatitis B (HBIG), tetanus (Hyper-Tet), and chickenpox (VZIG).
See also: immunotherapy
References in periodicals archive ?
We believe that passive immunotherapy may be efficaceous if administered very early in the course of illness, before the severity of a particular patient's disease course is known.
Passive immunotherapy product and byproduct sales also increased by 40% primarily due to byproduct sales and an increase in unit sales and unit price of Omrigam.
These include ARBs, acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), anti-TNF and more.
These include acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), plasminogen activator inhibitor-1, anti-TNF, GSK3 and more.
Safferstein previously served as Vice President, Business Development, Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products.
Our lead product, FavId(R), is an active immunotherapy being developed as a complement to the anti-CD20 passive immunotherapy Rituxan(R).
The current market leader in the treatment of NHL is Rituxan, a passive immunotherapy that marshals the immune system to kill the B-cells.
OMRIX, a commercial-stage Company, develops and markets innovative biosurgical and passive immunotherapy products, utilizing its proprietary protein purification technology and manufacturing know-how.
AC Immune's proprietary therapeutic approach against Alzheimer's Disease has resulted in the development of a vaccine as well as a passive immunotherapy with a selected monoclonal antibody which was highly active in animal models for Alzheimer's Disease.
Rituxan is a monoclonal antibody that is administered as a passive immunotherapy and, although a very successful treatment, is limited by its duration of remission, which is on the order of one year.

Full browser ?